Replies to post #112518 on Biotech Values

[mcbio]

Cardiovascular risk is tough to rule out. The size and length of RIGL trials conducted so far can't rule out cardio risk with increased blood pressure.

Keep in mind that, according to RIGL, the increased blood pressure typically only occurs during the first month of treatment. If a one-time adjustment in anti-hypertension medication is made at that time, there is no longer elevated blood pressure. So, I find it hard to believe that a very slight elevated blood pressure during the first month of treatment that is promptly resolved will somehow translate into increased cardiovascular risk years later. (There are patients that have been on treatment a few years now I believe and, again, there is no increased cardiovascular risks to date in FosD arms.)

If R788 works in anti-TNF failure patients, it would change risk/benefit profile for me.

As noted at Piper (#msg-58251171), they at least have a better inkling as to why TASKi3 failed and may be able to better design the Phase 3 trial in this patient population.